当前位置:首页>产品中心>单抗/多抗>HEK293T Human CD166/ALCAM Stable Cell Line|HEK293T人CD166/ALCAM稳定细胞系(靶标:人CD166/ALCAM稳定表达细胞系)

HEK293T Human CD166/ALCAM Stable Cell Line|HEK293T人CD166/ALCAM稳定细胞系(靶标:人CD166/ALCAM稳定表达细胞系)

  • 货号:RB9THC678818
  • 价格:面议
  • 点击:443
   一键复制产品信息 复制成功!

产品介绍

产品参数

宿主种属HEK293T
应用FCM
靶标CD166/ALCAM
稳定性和储存Frozen in liquid nitrogen.
登录号Q13740
背景信息

CD166 antigen (ALCAM) is a ~65 kDa protein. Cell adhesion molecule that mediates both heterotypic cell-cell contacts via its interaction with CD6, as well as homotypic cell-cell contacts. Promotes T-cell activation and proliferation via its interactions with CD6. Contributes to the formation and maturation of the immunological synapse via its interactions with CD6. Mediates homotypic interactions with cells that express ALCAM. Acts as a ligand for the LILRB4 receptor, enhancing LILRB4-mediated inhibition of T cell proliferation.

1. Hassan, NJ. et al. (2004) European journal of immunology 34, 930-40. PMID: 15048703
2. Ikeda, K. et al. (2004) The Journal of biological chemistry 279, 55315-23. PMID: 15496415
3. Zimmerman, AW. et al. (2006) Blood 107, 3212-20. PMID: 16352806
4. Iolyeva, M. et al. (2013) FASEB journal : official publication of the Federation of American Societies for Experimental Biology 27, 978-90. PMID: 23169771
5. Escoda-Ferran, C. et al. (2014) FEBS letters 588, 2805-13. PMID: 24945728
6. Bowen, MA. et al. (1995) The Journal of experimental medicine 181, 2213-20. PMID: 7760007
7. Gimferrer, I. et al. (2004) Journal of immunology (Baltimore, Md. : 1950) 173, 2262-70. PMID: 15294938
8. Xu, Z. et al. (2018) Journal of immunology (Baltimore, Md. : 1950) 200, 1207-1219. PMID: 29263213
9. Chitteti, BR. et al. (2014) Blood 124, 519-29. PMID: 24740813
产品特性Growth Properties: Adherent; Selection Marker: Puromycin (1 μg/mL)
种属Human
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Camrelizumab Neutralizing Recombinant Antibody |抗卡瑞利珠单抗中和重组抗体(靶标:卡瑞利珠单抗中和抗体) 670
Anti-Golimumab Neutralizing Recombinant Antibody |抗戈利木单抗中和重组抗体(靶标:戈利木单抗中和抗体) 490
Anti-Golimumab Neutralizing Recombinant Antibody |抗戈利木单抗中和重组抗体(靶标:戈利木单抗中和抗体) 721
Anti-Golimumab Neutralizing Recombinant Antibody |抗戈利木单抗中和重组抗体(靶标:戈利木单抗中和抗体) 408
Anti-Golimumab Neutralizing Recombinant Antibody |抗戈利木单抗中和重组抗体(靶标:戈利木单抗中和抗体) 570
Anti-Infliximab Non-Neutralizing Recombinant Antibody |抗英夫利昔单抗非中和重组抗体(靶标:英夫利昔单抗非中和抗体) 723
Anti-Infliximab Non-Neutralizing Recombinant Antibody |抗英夫利昔单抗非中和重组抗体(靶标:英夫利昔单抗非中和抗体) 728
Anti-Infliximab Neutralizing Recombinant Antibody |抗英夫利昔单抗中和重组抗体(靶标:英夫利昔单抗中和抗体) 813
Anti-Infliximab Neutralizing Recombinant Antibody |抗英夫利昔单抗中和重组抗体(靶标:英夫利昔单抗中和抗体) 637
Anti-Infliximab Neutralizing Recombinant Antibody |抗英夫利昔单抗中和重组抗体(靶标:英夫利昔单抗中和抗体) 441
Anti-Infliximab Neutralizing Recombinant Antibody |抗英夫利昔单抗中和重组抗体(靶标:英夫利昔单抗中和抗体) 541
Anti-Matuzumab Neutralizing Recombinant Antibody |抗马妥珠单抗中和重组抗体(靶标:马妥珠单抗中和抗体) 459
Anti-Matuzumab Neutralizing Recombinant Antibody |抗马妥珠单抗中和重组抗体(靶标:马妥珠单抗中和抗体) 681
Anti-Matuzumab Neutralizing Recombinant Antibody |抗马妥珠单抗中和重组抗体(靶标:马妥珠单抗中和抗体) 679
Anti-Matuzumab Neutralizing Recombinant Antibody |抗马妥珠单抗中和重组抗体(靶标:马妥珠单抗中和抗体) 691
Anti-Elotuzumab Non-Neutralizing Recombinant Antibody|抗埃罗妥珠单抗非中和重组抗体(靶标:埃罗妥珠单抗非中和抗体) 714
Anti-Elotuzumab Neutralizing Recombinant Antibody |抗埃罗妥珠单抗中和重组抗体(靶标:埃罗妥珠单抗中和抗体) 481
Anti-Elotuzumab Neutralizing Recombinant Antibody |抗埃罗妥珠单抗中和重组抗体(靶标:埃罗妥珠单抗中和抗体) 498
Anti-Oleclumab Neutralizing Recombinant Antibody |抗奥乐克单抗中和重组抗体(靶标:奥乐克单抗中和抗体) 442
Anti-Oleclumab Neutralizing Recombinant Antibody |抗奥乐克单抗中和重组抗体(靶标:奥乐克单抗中和抗体) 537
总计 33037 个记录,共 1652 页,当前第 1649 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00